BARCELONA, July 19, 2011 /PRNewswire/ --
- NT-KO-003, developed by Advancell and Neurotec Pharma, is the first MS drug with neuroprotective effects that does not cause immunosuppression.
- This treatment is one of the first to be administered orally, whereas the few treatments available in Spain require parenteral administration (intravenous or subcutaneous) and have significant side effects.
- NeuroAdvan, the Phase IIa clinical trial, will be led by Dr Pablo Villoslada, director of Neuroimmunology at IDIBAPS, Hospital Clinic de Barcelona, ??and conducted in 105 patients in 14 hospitals in Europe. It will represent an investment of 2.2 M €, part of which will be financed by the Catalan Local Government and the Ministry of Science and Innovation.
- This project brings to clinical proof of concept the first molecule arising from Neurotec´s research in the field of acute and chronic central nervous system diseases; Advancell reaffirms its business model consisting of the development of new drugs to Phase II, and to subsequently license them to a pharmaceutical company.
The biotechnological companies Advancell and Neurotec Pharma, both based in Barcelona Science Park (PCB), Spain, have announced the initiation of a clinical Phase IIa study with NT-KO-003, an innovative oral therapy for multiple sclerosis (MS). NT-KO-003 was codeveloped by both companies and its mechanism of action is completely different from the drugs currently used to treat this disease.
The clinical trial, called NeuroAdvan, will be conducted in 105 patients from 11 hospitals in Spain (4 of them in Catalonia) and 3 in Germany, and will be led by Dr Pablo Villoslada, director of Neuroimmunology at IDIBAPS, Hospital Clinic de Barcelona, Spain. The project is being conducted in collaboration with the MRI Analysis and Research Center in Neuroimaging and Multiple Sclerosis (CARM) at the Hospital Vall d´Hebron, Barcelona, led by Dr. Alex Rovira, and also with advice from Dr. Rafael Arroyo at the San Carlos Cinical Hospital, Madrid, Spainm and Dr. Xavier Montalban from Hospital Vall d´Hebron, Spain. Results from the study are expected in late 2012.
===========================================================
Remain CURRENT with Multiple Sclerosis news and information,
when registered at our MS Views and News website
.
.Providing You with 'MS Views and News', is what we do
.
On the 4th Wednesday of each month
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
Your donation will Help us to educate
"MS Views and News" is a 501©(3) organization as recognized
by the Internal Revenue Service
by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
0 comments:
Post a Comment